Loading...
Header Logo
Keywords
Last Name
Institution

AMY B HEIMBERGER

TitleProfessor
InstitutionMD Anderson
DepartmentNeurosurgery
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019 May; 142(3):499-509. PMID: 30847840.
      View in: PubMed
    2. Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 Mar 01; 111(3):292-300. PMID: 29947810.
      View in: PubMed
    3. Al-Holou WN, Hodges TR, Everson RG, Freeman J, Zhou S, Suki D, Rao G, Ferguson SD, Heimberger AB, McCutcheon IE, Prabhu SS, Lang FF, Weinberg JS, Wildrick DM, Sawaya R. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2019 Feb 25. PMID: 30799490.
      View in: PubMed
    4. Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 02 15; 10(1):862. PMID: 30770835.
      View in: PubMed
    5. Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 01 25; 10(1):448. PMID: 30683885.
      View in: PubMed
    6. Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 Jan 02; 129(1):137-149. PMID: 30307407.
      View in: PubMed
    7. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026. PMID: 29923182.
      View in: PubMed
    8. Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, Hong S, Xia X, Heimberger AB, Li S. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett. 2018 Oct 01; 433:176-185. PMID: 29991446.
      View in: PubMed
    9. Caruso H, Heimberger AB. Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma". Neuro Oncol. 2018 Jun 18; 20(7):1003-1004. PMID: 29648659.
      View in: PubMed
    10. Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018 Sep; 139(3):713-720. PMID: 29869738.
      View in: PubMed
    11. Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 Jun 01; 77(6):437-442. PMID: 29718398.
      View in: PubMed
    12. Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep; 139(2):469-478. PMID: 29846894.
      View in: PubMed
    13. Shen J, Song R, Hodges TR, Heimberger AB, Zhao H. Identification of metabolites in plasma for predicting survival in glioblastoma. Mol Carcinog. 2018 08; 57(8):1078-1084. PMID: 29603794.
      View in: PubMed
    14. Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219. PMID: 29572535.
      View in: PubMed
    15. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283. PMID: 29387478.
      View in: PubMed
    16. Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909. PMID: 29632728.
      View in: PubMed
    17. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018 01 08; 33(1):152. PMID: 29316430.
      View in: PubMed
    18. Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2018 Jan 30; 9(8):7822-7831. PMID: 29487694.
      View in: PubMed
    19. Shen J, Hodges TR, Song R, Gong Y, Calin GA, Heimberger AB, Zhao H. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018 Jan; 57(1):137-141. PMID: 28926136.
      View in: PubMed
    20. Jacobs DI, Liu Y, Gabrusiewicz K, Tsavachidis S, Armstrong GN, Zhou R, Wei J, Ivan C, Calin G, Molinaro AM, Rice T, Bracci PM, Hansen HM, Wiencke JK, Wrensch MR, Heimberger AB, Bondy ML. Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol. 2018 Jan; 136(1):33-39. PMID: 28965162.
      View in: PubMed
    21. Narang S, Kim D, Aithala S, Heimberger AB, Ahmed S, Rao D, Rao G, Rao A. Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget. 2017 Nov 24; 8(60):101244-101254. PMID: 29254160.
      View in: PubMed
    22. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057. PMID: 28371827.
      View in: PubMed
    23. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017 07 10; 32(1):42-56.e6. PMID: 28697342.
      View in: PubMed
    24. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048. PMID: 28687375.
      View in: PubMed
    25. Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M. Immune Checkpoint Inhibitors for Brain Metastases. Curr Oncol Rep. 2017 Jun; 19(6):38. PMID: 28417311.
      View in: PubMed
    26. Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357. PMID: 28389997.
      View in: PubMed
    27. Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017 03 11; 16(1):59. PMID: 28284220.
      View in: PubMed
    28. Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger AB. Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. 2017 03 01; 19(3):372-382. PMID: 27765835.
      View in: PubMed
    29. Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RG, Heimberger AB, Hu J. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. 2017 01; 49(1):75-86. PMID: 27841882.
      View in: PubMed
    30. Noh H, Yan J, Hong S, Kong LY, Gabrusiewicz K, Xia X, Heimberger AB, Li S. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget. 2016 Nov 01; 7(44):72021-72032. PMID: 27713131.
      View in: PubMed
    31. Salzillo TC, Hu J, Nguyen L, Whiting N, Lee J, Weygand J, Dutta P, Pudakalakatti S, Millward NZ, Gammon ST, Lang FF, Heimberger AB, Bhattacharya PK. Interrogating Metabolism in Brain Cancer. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):687-703. PMID: 27742110.
      View in: PubMed
    32. Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478. PMID: 27579614.
      View in: PubMed
    33. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66. PMID: 27370400.
      View in: PubMed
    34. Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJ. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother. 2016 06; 39(5):205-17. PMID: 27163741.
      View in: PubMed
    35. Xue J, Zhou A, Wu Y, Morris SA, Lin K, Amin S, Verhaak R, Fuller G, Xie K, Heimberger AB, Huang S. miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res. 2016 07 15; 76(14):4293-304. PMID: 27246830.
      View in: PubMed
    36. Hodges TR, Ferguson SD, Heimberger AB. Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol. 2016 07; 5(3):175-86. PMID: 27225028.
      View in: PubMed
    37. Zhao H, Heimberger AB, Lu Z, Wu X, Hodges TR, Song R, Shen J. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 2016 Apr 12; 7(15):20486-95. PMID: 26967252.
      View in: PubMed
    38. Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2). PMID: 26973881.
      View in: PubMed
    39. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. PMID: 27471611.
      View in: PubMed
    40. Lin J, Xu K, Wei J, Heimberger AB, Roth JA, Ji L. MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. J Gene Ther. 2016 Feb; 2(1). PMID: 27376157.
      View in: PubMed
    41. Ferguson SD, Srinivasan VM, Ghali MG, Heimberger AB. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope? Immunotherapy. 2016; 8(4):413-23. PMID: 26973123.
      View in: PubMed
    42. Liebelt BD, Finocchiaro G, Heimberger AB. Principles of immunotherapy. Handb Clin Neurol. 2016; 134:163-81. PMID: 26948354.
      View in: PubMed
    43. Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB. Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology. 2016 May; 5(5):e1117739. PMID: 27467917.
      View in: PubMed
    44. Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger AB. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48. PMID: 26658052.
      View in: PubMed
    45. Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii9-vii14. PMID: 26516226.
      View in: PubMed
    46. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res. 2015 Sep 01; 75(17):3505-18. PMID: 26330164.
      View in: PubMed
    47. Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 Feb; 18(2):195-205. PMID: 26323609.
      View in: PubMed
    48. Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst. 2015 Aug; 107(8). PMID: 25971300.
      View in: PubMed
    49. Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang S. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res. 2015 Jun 01; 75(11):2337-48. PMID: 25832656.
      View in: PubMed
    50. Ferguson SD, Srinivasan VM, Heimberger AB. The role of STAT3 in tumor-mediated immune suppression. J Neurooncol. 2015 Jul; 123(3):385-94. PMID: 25700834.
      View in: PubMed
    51. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61. PMID: 25586468.
      View in: PubMed
    52. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014 Nov 15; 20(22):5620-9. PMID: 25398845.
      View in: PubMed
    53. Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB. Therapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75. PMID: 25465288.
      View in: PubMed
    54. Gressot LV, Doucette TA, Yang Y, Fuller GN, Heimberger AB, Bögler O, Rao A, Latha K, Rao G. Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer. 2015 May 01; 136(9):2047-54. PMID: 25302990.
      View in: PubMed
    55. Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB, Sampson JH. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii20-5. PMID: 25342601.
      View in: PubMed
    56. Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol. 2016 07 03; 35(4):325-339. PMID: 25259408.
      View in: PubMed
    57. Xu S, Wei J, Wang F, Kong LY, Ling XY, Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, Fajt V, Levine JM, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014 Aug; 106(8). PMID: 24974128.
      View in: PubMed
    58. Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res. 2014 Sep; 2(9):867-77. PMID: 24938283.
      View in: PubMed
    59. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K. Mesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma. Cancer Cell. 2013 Sep 09; 24(3):331-46. PMID: 23993863.
      View in: PubMed
    60. Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013 Aug; 1(2):112-22. PMID: 24409449.
      View in: PubMed
    61. Wei J, Gabrusiewicz K, Heimberger A. The controversial role of microglia in malignant gliomas. Clin Dev Immunol. 2013; 2013:285246. PMID: 23983766.
      View in: PubMed
    62. Heimberger AB, Gilbert M, Rao G, Wei J. MicroRNAs as novel immunotherapeutics. Oncoimmunology. 2013 Aug 01; 2(8):e25124. PMID: 24083077.
      View in: PubMed
    63. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013 Jul 01; 73(13):3913-26. PMID: 23636127.
      View in: PubMed
    64. Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE, Mitchell DA, Heimberger AB, Bigner DD, Sampson JH. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013 Jun; 62(6):983-7. PMID: 23591978.
      View in: PubMed
    65. Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, McCutcheon IE, Prabhu SS, Heimberger AB, Sawaya R, Wang X, Qiao W, Hess K, Lang FF. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013 Apr; 118(4):873-883. PMID: 23394340.
      View in: PubMed
    66. de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48. PMID: 23013619.
      View in: PubMed
    67. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45. PMID: 22753228.
      View in: PubMed
    68. Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger AB. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44. PMID: 22488042.
      View in: PubMed
    69. Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):246-55. PMID: 22319219.
      View in: PubMed
    70. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4. PMID: 21593697.
      View in: PubMed
    71. Jethwa K, Wei J, McEnery K, Heimberger AB. miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond). 2011 Dec; 1(12):1637-1650. PMID: 22468222.
      View in: PubMed
    72. Heimberger AB. The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies. Surg Neurol Int. 2011; 2:163. PMID: 22140648.
      View in: PubMed
    73. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17. PMID: 21792892.
      View in: PubMed
    74. Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, Wang Y, Cahill D, Levine N, Prabhu S, Rao G, Sawaya R, Heimberger AB. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011 Jul 15; 17(14):4642-9. PMID: 21490182.
      View in: PubMed
    75. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195. PMID: 21283755.
      View in: PubMed
    76. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan; 13(1):3-13. PMID: 21149252.
      View in: PubMed
    77. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33. PMID: 21149254.
      View in: PubMed
    78. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9. PMID: 20921459.
      View in: PubMed
    79. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33. PMID: 20921210.
      View in: PubMed
    80. Hatiboglu MA, Wei J, Wu AS, Heimberger AB. Immune therapeutic targeting of glioma cancer stem cells. Target Oncol. 2010 Sep; 5(3):217-27. PMID: 20737294.
      View in: PubMed
    81. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov; 12(11):1113-25. PMID: 20667896.
      View in: PubMed
    82. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61. PMID: 20388845.
      View in: PubMed
    83. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, Lang FF, Heimberger AB. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010 Jan 15; 16(2):461-73. PMID: 20068105.
      View in: PubMed
    84. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010 Jan; 9(1):67-78. PMID: 20053772.
      View in: PubMed
    85. Humphries W, Wei J, Sampson JH, Heimberger AB. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am. 2010 Jan; 21(1):125-37. PMID: 19944972.
      View in: PubMed
    86. Kanaly CW, Ding D, Heimberger AB, Sampson JH. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am. 2010 Jan; 21(1):95-109. PMID: 19944970.
      View in: PubMed
    87. Humphries W, Wang Y, Qiao W, Reina-Ortiz C, Abou-Ghazal MK, Crutcher LM, Wei J, Kong LY, Sawaya R, Rao G, Weinberg J, Prabhu SS, Fuller GN, Heimberger AB. yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2009 Nov 09; 7:92. PMID: 19900287.
      View in: PubMed
    88. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009 Oct; 19(4):713-23. PMID: 19744042.
      View in: PubMed
    89. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct; 8(10):2773-9. PMID: 19825799.
      View in: PubMed
    90. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009 Aug; 9(8):1087-98. PMID: 19591631.
      View in: PubMed
    91. Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Sampson JH, Chang S, Prados M, Wiencke JK, Wrensch M. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009 Aug 01; 125(3):680-7. PMID: 19408307.
      View in: PubMed
    92. Murat A, Migliavacca E, Hussain SF, Heimberger AB, Desbaillets I, Hamou MF, Rüegg C, Stupp R, Delorenzi M, Hegi ME. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009 Jun 17; 4(6):e5947. PMID: 19536297.
      View in: PubMed
    93. Kim SS, McCutcheon IE, Suki D, Weinberg JS, Sawaya R, Lang FF, Ferson D, Heimberger AB, DeMonte F, Prabhu SS. Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery. 2009 May; 64(5):836-45; discussion 345-6. PMID: 19404147.
      View in: PubMed
    94. Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106. PMID: 20214040.
      View in: PubMed
    95. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35. PMID: 19088040.
      View in: PubMed
    96. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32. PMID: 19002459.
      View in: PubMed
    97. Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov. 2008 Nov; 3(3):179-88. PMID: 18991807.
      View in: PubMed
    98. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68. PMID: 18794085.
      View in: PubMed
    99. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30; 339(1):74-81. PMID: 18775433.
      View in: PubMed
    100. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008 Aug 15; 14(16):5166-72. PMID: 18698034.
      View in: PubMed
    101. Wei J, DeAngulo G, Sun W, Hussain SF, Vasquez H, Jordan J, Weinberg J, Wolff J, Koshkina N, Heimberger AB. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother. 2009 Feb; 58(2):259-70. PMID: 18594817.
      View in: PubMed
    102. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008 Oct; 20(5):267-75. PMID: 18539480.
      View in: PubMed
    103. Brem SS, Bierman PJ, Black P, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Glass J, Grossman SA, Heimberger AB, Junck L, Linette GP, Loeffler JJ, Maor MH, Moots P, Mrugala M, Nabors LB, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Shrieve DC, Sills AK. Central nervous system cancers. J Natl Compr Canc Netw. 2008 May; 6(5):456-504. PMID: 18492461.
      View in: PubMed
    104. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008 Feb; 10(1):98-103. PMID: 18079360.
      View in: PubMed
    105. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6. PMID: 17942891.
      View in: PubMed
    106. Paz N, Levanon EY, Amariglio N, Heimberger AB, Ram Z, Constantini S, Barbash ZS, Adamsky K, Safran M, Hirschberg A, Krupsky M, Ben-Dov I, Cazacu S, Mikkelsen T, Brodie C, Eisenberg E, Rechavi G. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007 Nov; 17(11):1586-95. PMID: 17908822.
      View in: PubMed
    107. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007 Jun 15; 13(12):3559-67. PMID: 17575219.
      View in: PubMed
    108. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007 Jun 01; 25(16):2288-94. PMID: 17538175.
      View in: PubMed
    109. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008 Jan; 57(1):123-31. PMID: 17522861.
      View in: PubMed
    110. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, Fuller GN, Aldape KD. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006 Jul 01; 12(13):3935-41. PMID: 16818690.
      View in: PubMed
    111. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3):261-79. PMID: 16775224.
      View in: PubMed
    112. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB. Innate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006 Mar 30; 4:15. PMID: 16573834.
      View in: PubMed
    113. Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med. 2005 Oct 19; 3:38. PMID: 16236164.
      View in: PubMed
    114. Hussain SF, Heimberger AB. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005 Oct; 5(5):777-90. PMID: 16221048.
      View in: PubMed
    115. Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Fine HA, Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V, Loeffler JJ, Maor MH, Narayana A, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Rosenfeld SS, Shrieve DC, Sills AK, Spence AM, Vrionis FD. Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):644-90. PMID: 16194456.
      View in: PubMed
    116. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005 Feb 15; 11(4):1462-6. PMID: 15746047.
      View in: PubMed
    117. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res. 2005 Jan 01; 11(1):267-72. PMID: 15671555.
      View in: PubMed
    118. Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Mechanisms of action of rapamycin in gliomas. Neuro Oncol. 2005 Jan; 7(1):1-11. PMID: 15701277.
      View in: PubMed
    119. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5. PMID: 15009722.
      View in: PubMed
    120. McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, Lev DC, Bar-Eli M. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003 Dec 15; 9(17):6560-6. PMID: 14695161.
      View in: PubMed
    121. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003 Sep 15; 9(11):4247-54. PMID: 14519652.
      View in: PubMed
    122. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. 2002 Nov; 8(11):3496-502. PMID: 12429640.
      View in: PubMed
    123. Heimberger AB, Wiltshire RN, Bronec R, McLendon RE, Cummings TJ. Biphasic malignant meningioma: a comparative genomic hybridization study. Clin Neuropathol. 2002 Nov-Dec; 21(6):258-64. PMID: 12489674.
      View in: PubMed
    124. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 2002 Jan; 50(1):158-64; discussion 164-6. PMID: 11844246.
      View in: PubMed
    125. Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res. 2000 Oct; 6(10):4148-53. PMID: 11051269.
      View in: PubMed
    126. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol. 2000 Feb 01; 103(1):16-25. PMID: 10674985.
      View in: PubMed
    127. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):6065-9. PMID: 1385868.
      View in: PubMed
    128. Murphy KM, Heimberger AB, Loh DY. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science. 1990 Dec 21; 250(4988):1720-3. PMID: 2125367.
      View in: PubMed
    129. Levén S, Heimberger A, Eisenstark A. Catalase HPI influences membrane permeability in Escherichia coli following near-UV stress. Biochem Biophys Res Commun. 1990 Sep 28; 171(3):1224-8. PMID: 2222441.
      View in: PubMed
    130. Heimberger A, Eisenstark A. Compartmentalization of catalases in Escherichia coli. Biochem Biophys Res Commun. 1988 Jul 15; 154(1):392-7. PMID: 3293564.
      View in: PubMed
    131. Reply to M.C. Chamberlain. Journal of Clinical Oncology. 29.
    132. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology. 18:195-205.
    133. MicroRNAs as novel immunotherapeutics. OncoImmunology. 2.
    134. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology. 18:639-648.
    135. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant. International Reviews of Immunology.
    136. Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. OncoImmunology.
    137. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget. 7:72021-72032.
    138. Synergistic effect of immunotherapy and chemotherapy in cancers. Letters in Drug Design and Discovery. 3:513-523.
    139. Cytomegalovirus-targeted immunotherapy and glioblastoma. Immunotherapy. 8:413-423.
    140. Principles of immunotherapy. 163-181.
    141. The natural history of EGFR and EGFRvIII in glioblastoma patients. Journal of Translational Medicine. 3.
    142. Reply to J.W. Locasale et al. Journal of Clinical Oncology. 30:338-339.
    143. Redirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor. Journal of Immunotherapy. 39:205-217.
    144. Reply to M.S. Lesniak. Journal of Clinical Oncology. 29:3105-3106.
    145. The role of STAT3 in tumor-mediated immune suppression. Journal of Neuro-Oncology. 123:385-394.
    146. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 7:20486-20495.
    147. Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology.
    148. Interrogating Metabolism in Brain Cancer. Magnetic Resonance Imaging Clinics of North America. 24:687-703.
    149. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 7:69466-69478.
    150. The role of glioma microenvironment in immune modulation. Letters in Drug Design and Discovery. 3:443-453.
    151. Erratum. Cancer Immunology, Immunotherapy. 57:133.
    152. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature Genetics. 49:75-86.
    153. miR-182-5p induced by STAT3 activation promotes glioma tumorigenesis. Cancer Research. 76:4293-4304.
    154. Innate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine. 4.
    155. Immune checkpoint blockade as a potential therapeutic target. Neuro-Oncology. 18:1357-1366.
    156. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma. Neuro-Oncology. 17:854-861.
    HEIMBERGER's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description